Quoin Pharmaceuticals, Ltd. - American Depositary Shares QNRX 深 沪
等待开盘 09-26 09:30:00 美东时间
7.41
+0.390
+5.56%
华盛通- 最 高7.6659
- 今 开7.10
- 成交量 4.65万股
- 最 低 7.08
- 昨 收 7.02
- 总市值 3741.84万
- 52周最高 54.95
- 市盈率 静 --
- 换手率 0.92%
- 52周最低 5.01
- 委 比 -99.67%
- 总股本 504.97万
- 历史最高 1417500.00
- 量 比 1.13
- 振 幅 8.35%
- 历史最低 5.824
- 每 手 1
- 风险率 7.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why New Fortress Energy Shares Are Trading Higher By 41%; Here Are 20 Stocks Moving Premarket
Shares of New Fortress Energy Inc. (NASDAQ:NFE) rose sharply in pre-market trad...
09-17 17:15
Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome
Quoin Pharmaceuticals releases the fifth episode of its NETHERTON NOW video series, featuring twin sisters Allie and Kaleigh Fasanella sharing their lifelong struggles with Netherton Syndrome. The video highlights the social, emotional, and physical challenges of the rare genetic skin disease, emphasizing the need for supportive communities and approved treatments. The episode also discusses Quoin's QRX003, which is in pivotal clinical trials for...
09-09 12:30
Quoin Pharmaceuticals Announces CFO Departure Agreement
Quoin Pharmaceuticals ( ($QNRX) ) has shared an update. Quoin Pharmaceuticals L...
08-27 18:28
Quoin Pharmaceuticals’ NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome
Quoin Pharmaceuticals' NETHERTON NOW campaign has reached a major milestone, surpassing one million video views and 14 million impressions. The initiative aims to raise awareness about Netherton Syndrome (NS), a rare genetic skin disease, by sharing personal stories and clinical insights. Quoin's lead candidate, QRX003, is in late-stage trials for NS treatment, with enrollment expected to complete early to mid-2026. The company remains focused on...
08-21 12:30
Quoin Pharmaceuticals appoints Sally Lawlor as CFO
Quoin Pharmaceuticals (NASDAQ:QNRX) on Monday announced the appointment of Sally Lawlor as its new Chief Financial Officer as the company advances its lead product candidate, QRX003, through pivotal c...
08-18 20:36
Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton
Quoin Pharmaceuticals released the fourth episode of its NETHERTON NOW video series, featuring Mandy Aldwin-Easton, a Netherton Syndrome patient and advocate. The video highlights the severe physical and emotional toll of the disease, including delayed diagnosis, chronic pain, and lack of effective treatments. Mandy’s story underscores the urgent need for better therapies. Quoin is advancing QRX003, a topical lotion, in pivotal trials, with promi...
08-12 12:30
Quoin Pharmaceuticals Non-GAAP EPS of -$6.28
Quoin Pharmaceuticals press release (NASDAQ:QNRX): Q2 Non-GAAP EPS of -$6.28. Quoin had approximately $7.8 million in cash, cash equivalents, and marketable securities as of June 30, 2025. The Company...
08-07 21:23
Quoin Pharmaceuticals Q2 EPS $(6.28) Beats $(7.41) Estimate
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(6.28) per share which beat the analyst consensus estimate of $(7.41) by 15.25 percent. This is a 54.09 percent increase over losses of $(13.68) per share
08-07 20:34
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced it will release its second-quarter 2025 financial results before the market opens on August 7, 2025. The announcement will include an operational update and financial highlights. The company, focused on rare and orphan diseases, has four products in development targeting conditions like Netherton Syndrome and Epidermolysis Bullosa. For more details, visit www.quoinpharma.com or contact Michael M...
07-31 12:30
